Article

High sdLDL-C Levels Enhance Atherosclerotic Cardiovascular Disease Risk

Author(s):

A new study from the American Heart Association Scientific Sessions 2021 found that atherosclerotic cardiovascular disease risk increases with sdLDL-C levels, regardless of sex or race.

Ernst J Schaefer, MD

Ernst J Schaefer, MD

According to the results, when small dense low-density lipoprotein cholesterol (sdLDL-C) value levels reach 50 mg/dL or higher, it’s associated with a 50% increased 10-year inclusive atherosclerotic cardiovascular disease (ASCVD) risk. This applied to all participants regardless of sex or race, which makes it an important atherosclerotic cardiovascular disease risk enhancer.

The study, “Atherosclerotic Cardiovascular Disease Risk and Small Dense Low-Density Lipoprotein Cholesterol in Men, Women, African Americans and Non-African Americans”, was conducted by a team of investigators led by Ernst J Schaefer, MD, Tufts University. It was presented at American Heart Association Scientific Sessions 2021.

Investigators predicted that small dense low-density lipoprotein is an independent atherosclerotic cardiovascular disease risk factor in both men and women as well as African American people and non-African American people.

The Outcome

The standard risk factors measured in this study were significant for hard and inclusive atherosclerotic cardiovascular disease in men, women, African American people and non-African American people on univariate statistical analysis.

Investigators found that when added to the pooled cohort equation for hard and inclusive atherosclerotic cardiovascular disease, small dense low-density lipoprotein was a significant risk factor in all subjects, as well as inclusive atherosclerotic cardiovascular disease in all subgroups.

The hazard ratios (HR) and confidence intervals (CI) for incident inclusive atherosclerotic cardiovascular disease were all significant when patients with elevated small dense low-density lipoprotein levels of ≥50 mg/dL were compared to patients with optimal levels of <25 mg/dL after adjustment for all standard risk factors.

The significant hazard ratios and confidence intervals were all significant at P<0.01: all patients (HR 1.54, CI 1.30-1.83), men (HR 1.59, CI 1.27-1.99), women (HR 1.51, CI 1.05-1.27), non-African American patients (HR 1.49, CI 1.24-1.80[CLA3]), and African American patients (HR 1.88, CI 1.23-2.89).

The Evaluation

The participants were pooled from 3 studies and all free of inclusive atherosclerotic cardiovascular disease at baseline. The median age of the 15,933 participants was 62 years. 56.7% of participants were female, 19.7% of participants were African American.

Patients were analyzed for 10 years for incident hard ASCVD and inclusive ASCVD. Angioplasty (6.1%) and coronary artery bypass (9.7%) were also included.

At baseline, an automated analysis measured serum small dense low-density lipoprotein cholesterol levels and all risk factor information was gathered.

Traditional cardiovascular risk factors and small dense low-density lipoprotein cholesterol levels were examined in 10-year hard and inclusive atherosclerotic cardio vascular disease risk by using a univariate and multivariate regression analysis.

Investigators found that a 50% increased 10-year inclusive atherosclerotic cardiovascular disease risk was associated with small dense low-density lipoprotein cholesterol values that reach 50 mg/dL or higher among all participants, regardless of sex or race.

Related Videos
The APAC Recap: Cardiomyopathy at CAPP Live 2024 with Greg Duck, PA-C | Image Credit: APAC
The APAC Recap: Peripheral Artery Disease at CAPP Live 2024 with Bob Ross, PA-C | Image Credit: APAC
AMG0001 Advances Healing in CLTI with David G. Armstrong, DPM, PhD, and Michael S. Conte, MD | Image Credit: Canva
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
© 2024 MJH Life Sciences

All rights reserved.